Immuneering Corporation

Immuneering is a clinical-stage oncology company developing Deep Cyclic Inhibitors, a therapeutic approach intended to outpace tumor adaptation while limiting effects on healthy cells. Its lead candidate, atebimetinib, is an oral MEK inhibitor being advanced for pancreatic cancer, with additional studies in lung cancer. The company uses its platform to develop therapies across a wide range of cancers, aiming to extend survival while preserving patients’ quality of life.